Company intelligence / Profile preview

BioMin Technologies

London, England, United Kingdombiomin.co.uk ↗

Ownership: Private
Development stage: Commercial

Overview

Clinical studies have shown that BioMin’s slow-release fluoride and bioactive glass technology provides up to twelve hours of continuous protection against tooth sensitivity and supports enamel remineralization. Products are CE certified as class IIb medical devices, with regulatory approval in the EU, Australia, and the US.

Therapeutic areas: Other
Modalities: Biologic (bioactive glass)Device (toothpaste as a regulated medical device)Small molecule (fluoride and calcium/phosphate ions)
Industry: Therapeutic Medical Devices

Drug pipeline

3 assets

BioMin F

Commercial

Indications: Dental hypersensitivity, Enamel protection

2 more assets in the full pipeline.

Request access →

Partnerships

Distribution partners worldwide (specific names not listed)Queen Mary University of London & Imperial College London—academic origins/collaborations

Beyond the preview

Go deeper on BioMin Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioMin Technologies.

Explore the full profile